Kennewick, WA, April 23, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a leader in innovative cancer therapies, announced today a record-breaking first quarter for its IsoPet Animal Cancer Division. The company's patented Precision Radionuclide Therapy (PRnT) treated an unprecedented number of pets in Q1 2025, marking a 150% year-over-year increase in treatment volume. This milestone underscores IsoPet's growing role as a transformative, non-invasive solution for veterinary oncology. Q1 2025 Highlights ...